A Multicentre, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of Rosiglitazone When Administered to Patients With Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Phase 3
This is an extension study to 49653/015, 49653/020, and 49653/025. Reporting and analysis plan is not available for this study. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
June 2014